30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
GSK plc trades at 16.2x earnings, 12% below its 5-year average of 18.3x, sitting at the 17th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 32%. On a free-cash-flow basis, the stock trades at 15.1x P/FCF, roughly in line with the 5-year average of 14.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $118.7B | $100.9B | $70.0B | $76.2B | $71.8B | $71.5B | $74.2B | $94.3B | $76.0B | $70.1B | $75.6B |
| Enterprise Value | $137.9B | $115.2B | $83.3B | $95.4B | $89.0B | $98.4B | $102.7B | $128.5B | $98.2B | $83.4B | $89.5B |
| P/E Ratio → | 16.16 | 18.03 | 27.27 | 15.44 | 14.64 | 16.33 | 12.87 | 20.25 | 20.99 | 45.47 | 83.72 |
| P/S Ratio | 2.76 | 3.16 | 2.23 | 2.51 | 2.45 | 2.89 | 3.05 | 2.79 | 2.47 | 2.32 | 2.71 |
| P/B Ratio | 5.68 | 6.34 | 5.35 | 4.67 | 7.11 | 2.47 | 2.61 | 3.88 | 20.69 | 20.09 | 15.24 |
| P/FCF | 15.14 | 17.33 | 19.61 | 12.17 | 10.63 | 13.49 | 11.42 | 16.10 | 11.47 | 14.86 | 18.24 |
| P/OCF | 12.35 | 14.13 | 10.69 | 9.65 | 8.79 | 8.99 | 8.79 | 11.76 | 9.02 | 10.13 | 11.64 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
GSK plc's enterprise value stands at 9.6x EBITDA, 20% below its 5-year average of 11.9x. The Healthcare sector median is 13.8x, placing the stock at a 31% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.61 | 2.66 | 3.15 | 3.04 | 3.99 | 4.22 | 3.81 | 3.19 | 2.76 | 3.21 |
| EV / EBITDA | 9.57 | 10.76 | 12.68 | 10.55 | 10.38 | 15.19 | 12.79 | 14.15 | 13.38 | 13.87 | 20.47 |
| EV / EBIT | 14.62 | 14.54 | 20.24 | 14.05 | 13.79 | 22.56 | 17.06 | 18.09 | 17.87 | 19.56 | 33.70 |
| EV / FCF | — | 19.79 | 23.33 | 15.25 | 13.18 | 18.58 | 15.81 | 21.93 | 14.82 | 17.68 | 21.59 |
Margins and return-on-capital ratios measuring operating efficiency
GSK plc earns an operating margin of 21.9%. Return on equity of 38.5% is exceptionally high. ROIC of 18.6% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.5% | 72.5% | 71.2% | 71.8% | 67.4% | 66.9% | 67.4% | 64.9% | 66.8% | 65.7% | 66.7% |
| Operating Margin | 21.9% | 21.9% | 12.8% | 22.2% | 21.9% | 17.6% | 24.6% | 20.6% | 17.8% | 13.5% | 9.3% |
| Net Profit Margin | 17.5% | 17.5% | 8.2% | 16.2% | 51.0% | 17.8% | 23.6% | 13.8% | 11.8% | 5.1% | 3.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 38.5% | 38.5% | 17.5% | 37.3% | 76.7% | 15.3% | 21.8% | 33.2% | 101.2% | 36.3% | 13.2% |
| ROA | 9.3% | 9.3% | 3.8% | 7.3% | 17.9% | 4.0% | 5.3% | 5.7% | 6.3% | 2.7% | 1.6% |
| ROIC | 18.6% | 18.6% | 9.7% | 16.1% | 11.6% | 5.8% | 7.8% | 12.4% | 19.3% | 17.2% | 10.1% |
| ROCE | 18.1% | 18.1% | 9.3% | 15.7% | 11.4% | 5.6% | 7.8% | 12.7% | 16.8% | 11.7% | 6.5% |
Solvency and debt-coverage ratios — lower is generally safer
GSK plc carries a Debt/EBITDA ratio of 1.7x, which is manageable (47% below the sector average of 3.1x). Net debt stands at $14.3B ($17.7B total debt minus $3.4B cash). Interest coverage of 10.2x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.11 | 1.11 | 1.30 | 1.41 | 2.08 | 1.13 | 1.30 | 1.66 | 7.10 | 4.90 | 3.79 |
| Debt / EBITDA | 1.65 | 1.65 | 2.58 | 2.54 | 2.45 | 5.05 | 4.62 | 4.45 | 3.55 | 2.84 | 4.30 |
| Net Debt / Equity | — | 0.90 | 1.02 | 1.18 | 1.71 | 0.93 | 1.00 | 1.41 | 6.04 | 3.80 | 2.80 |
| Net Debt / EBITDA | 1.34 | 1.34 | 2.02 | 2.13 | 2.01 | 4.16 | 3.55 | 3.76 | 3.02 | 2.21 | 3.18 |
| Debt / FCF | — | 2.45 | 3.72 | 3.07 | 2.56 | 5.09 | 4.39 | 5.84 | 3.35 | 2.81 | 3.35 |
| Interest Coverage | 10.23 | 10.23 | 6.11 | 8.70 | 7.52 | 5.56 | 6.70 | 7.63 | 7.37 | 5.57 | 3.53 |
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.82x is below 1.0, meaning current liabilities exceed current assets — though the company's $3.4B cash position helps mitigate short-term liquidity concerns. The current ratio has declined from 0.88x to 0.82x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.82 | 0.82 | 0.78 | 0.88 | 0.91 | 0.79 | 0.91 | 0.81 | 0.75 | 0.60 | 0.88 |
| Quick Ratio | 0.54 | 0.54 | 0.52 | 0.62 | 0.68 | 0.54 | 0.64 | 0.56 | 0.51 | 0.39 | 0.61 |
| Cash Ratio | 0.16 | 0.16 | 0.17 | 0.25 | 0.35 | 0.18 | 0.29 | 0.20 | 0.18 | 0.15 | 0.26 |
| Asset Turnover | — | 0.52 | 0.53 | 0.40 | 0.49 | 0.23 | 0.22 | 0.32 | 0.53 | 0.54 | 0.47 |
| Inventory Turnover | 1.48 | 1.48 | 1.60 | 1.22 | 1.86 | 1.04 | 0.97 | 1.51 | 1.87 | 1.86 | 1.82 |
| Days Sales Outstanding | — | 88.48 | 69.79 | 113.58 | 77.40 | 160.77 | 148.82 | 102.40 | 74.87 | 68.83 | 74.48 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
GSK plc returns 2.8% to shareholders annually primarily through dividends. A payout ratio of 44.9% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 6.2% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.8% | 2.5% | 3.5% | 3.7% | 6.0% | 5.6% | 5.4% | 4.2% | 5.2% | 5.6% | 6.4% |
| Payout Ratio | 44.9% | 44.9% | 94.9% | 56.7% | 28.6% | 91.2% | 69.2% | 85.1% | 108.4% | 255.0% | 531.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.2% | 5.5% | 3.7% | 6.5% | 6.8% | 6.1% | 7.8% | 4.9% | 4.8% | 2.2% | 1.2% |
| FCF Yield | 6.6% | 5.8% | 5.1% | 8.2% | 9.4% | 7.4% | 8.8% | 6.2% | 8.7% | 6.7% | 5.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% |
| Total Shareholder Yield | 2.8% | 2.5% | 3.5% | 3.7% | 6.0% | 5.6% | 5.4% | 4.2% | 5.2% | 5.7% | 6.5% |
| Shares Outstanding | — | $2.1B | $2.1B | $2.1B | $2.0B | $1.6B | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B |
Compare GSK with 4 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| GSKYou | $119B | 16.2 | 9.6 | 15.1 | 72.5% | 21.9% | 38.5% | 18.6% | 1.7 |
| MRK | $307B | 17.0 | 9.9 | — | 81.5% | 41.2% | 37.1% | 32.6% | — |
| PFE | $157B | 20.3 | 7.7 | — | 70.3% | 24.7% | 8.6% | 9.4% | — |
| SNY | $118B | 20.3 | 11.9 | 11.2 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
| GRFS | $2B | 33.5 | 6.8 | 3.8 | 38.7% | 16.5% | 1.9% | 5.0% | 6.2 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how GSK stacks up against sector leader Merck & Co., Inc..
Start ComparisonGSK plc's current P/E ratio is 16.2x. The historical average is 27.6x. This places it at the 17th percentile of its historical range.
GSK plc's current EV/EBITDA is 9.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.2x.
GSK plc's return on equity (ROE) is 38.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 61.5%.
Based on historical data, GSK plc is trading at a P/E of 16.2x. This is at the 17th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
GSK plc's current dividend yield is 2.77% with a payout ratio of 44.9%.
GSK plc has 72.5% gross margin and 21.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
GSK plc's Debt/EBITDA ratio is 1.7x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.